Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.
Bibliographical noteFunding Information:
W.C.K., T.S., and J.G. are supported by the Human Vaccines Project donor network. A.M. is supported by NIAID. C.M.C., M.J.C., and A.A.K. are funded by the Canadian Institutes for Health Research Rapid Response Grant for COVID-19. Y.K. is supported by a Research Program on Emerging and Re-emerging Infectious Diseases from AMED (19fk0108113). Y.K. and G.N. are supported by NIAID (grant no. HHSN272201400008C). T.M.R. is supported by an Emory-UGA-CEIRS grant (no. HHSN272201400004C). S.S.-C. is supported in part by ALSAC and by NIAID (grant no. HHSN272201400006C). T.M.R. and S.S.-C. are also supported by NIAID (grant no. 75N93019C00052). M.T.O., K.A.M., and J.T.O. are supported by the Wellcome Trust and by NIAID (grant no. HHSN272201400006C). Y.K. has received funding from Bharat Biotech.
Copyright © 2021 The Authors.
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't